PDF(Pubmed)
Abstract：
BACKGROUND: Opinions in the literature on the impact of cancer on patients with haemophilia are contradictory. There is a lack of data on the clinical presentation and management of cancer in patients with haemophilia (PWH).
METHODS: Papers were found following a comprehensive search in PubMed, Google Scholar, and Scopus using the terms \"cancer\" and \"haemophilia\" without time limits and using the English language as a filter. The references from all the retrieved original articles and reviews were assessed for additional relevant articles.
RESULTS: The emergence of malignancies is one of the important causes of morbidity and mortality in PWH. In the past decade, the literature mainly focused on the epidemiology and outcome of blood-borne cancers in the haemophilia patient group, as the incidence of hepatitis B virus (HBV), hepatitis C (HCV), and HIV infection were high among them. However, with the introduction of recombinant clotting factor concentrates (CFCs), physicians now pay attention to non-virus-related malignancies. Bleeding and thrombotic complications are important causes of morbidity and mortality in critically ill patients with cancer; replacement therapy with factor VIII or IX or others should be maintained during antitumour treatment.
CONCLUSIONS: Overall, managing cancer in patients with haemophilia requires careful evaluation and individualised planning involving a multidisciplinary team of physicians experienced in haematology, oncology, and surgery.
METHODS: Papers were found following a comprehensive search in PubMed, Google Scholar, and Scopus using the terms \"cancer\" and \"haemophilia\" without time limits and using the English language as a filter. The references from all the retrieved original articles and reviews were assessed for additional relevant articles.
RESULTS: The emergence of malignancies is one of the important causes of morbidity and mortality in PWH. In the past decade, the literature mainly focused on the epidemiology and outcome of blood-borne cancers in the haemophilia patient group, as the incidence of hepatitis B virus (HBV), hepatitis C (HCV), and HIV infection were high among them. However, with the introduction of recombinant clotting factor concentrates (CFCs), physicians now pay attention to non-virus-related malignancies. Bleeding and thrombotic complications are important causes of morbidity and mortality in critically ill patients with cancer; replacement therapy with factor VIII or IX or others should be maintained during antitumour treatment.
CONCLUSIONS: Overall, managing cancer in patients with haemophilia requires careful evaluation and individualised planning involving a multidisciplinary team of physicians experienced in haematology, oncology, and surgery.
摘要：
背景：文献中关于癌症对血友病患者的影响的观点是矛盾的。缺乏关于血友病（PWH）患者的癌症临床表现和管理的数据。
方法：在PubMed中进行全面搜索后发现了论文，谷歌学者，和Scopus使用术语“癌症”和“血友病”，没有时间限制，并使用英语作为过滤器。对所有检索到的原始文章和评论的参考文献进行了评估，以获取其他相关文章。
结果：恶性肿瘤的出现是PWH发病和死亡的重要原因之一。在过去的十年里,文献主要集中在血友病患者组中血源性癌症的流行病学和结果，作为乙型肝炎病毒（HBV）的发病率，丙型肝炎（HCV），其中艾滋病毒感染率很高。然而,随着重组凝血因子浓缩物(CFC)的引入，医生现在关注非病毒相关的恶性肿瘤.出血和血栓性并发症是危重癌症患者发病和死亡的重要原因；在抗肿瘤治疗期间，应维持因子VIII或IX或其他替代治疗。
结论：总体而言，血友病患者的癌症管理需要仔细的评估和个性化的规划，涉及多学科的医生团队在血液学经验丰富，肿瘤学,和手术。
方法：在PubMed中进行全面搜索后发现了论文，谷歌学者，和Scopus使用术语“癌症”和“血友病”，没有时间限制，并使用英语作为过滤器。对所有检索到的原始文章和评论的参考文献进行了评估，以获取其他相关文章。
结果：恶性肿瘤的出现是PWH发病和死亡的重要原因之一。在过去的十年里,文献主要集中在血友病患者组中血源性癌症的流行病学和结果，作为乙型肝炎病毒（HBV）的发病率，丙型肝炎（HCV），其中艾滋病毒感染率很高。然而,随着重组凝血因子浓缩物(CFC)的引入，医生现在关注非病毒相关的恶性肿瘤.出血和血栓性并发症是危重癌症患者发病和死亡的重要原因；在抗肿瘤治疗期间，应维持因子VIII或IX或其他替代治疗。
结论：总体而言，血友病患者的癌症管理需要仔细的评估和个性化的规划，涉及多学科的医生团队在血液学经验丰富，肿瘤学,和手术。
